Literature DB >> 17924103

Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae.

Fred H Laningham1, Larry E Kun, Wilburn E Reddick, Robert J Ogg, E Brannon Morris, Ching-Hon Pui.   

Abstract

INTRODUCTION: During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL). Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord. The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. METHODS AND
RESULTS: In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemia patients with a variety of acute neurological conditions. A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy. Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings. Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity.
CONCLUSION: Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity. Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children, and often suggest specific etiologies. Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy. It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.

Entities:  

Mesh:

Year:  2007        PMID: 17924103      PMCID: PMC2386669          DOI: 10.1007/s00234-007-0300-7

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  38 in total

1.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

Authors:  R F Stevens; I M Hann; K Wheatley; R G Gray
Journal:  Br J Haematol       Date:  1998-04       Impact factor: 6.998

3.  Minor changes on cranial MRI during treatment in children with acute lymphoblastic leukaemia.

Authors:  E Pääkkö; L Vainionpää; J Pyhtinen; M Lanning
Journal:  Neuroradiology       Date:  1996-04       Impact factor: 2.804

4.  Posterior reversible encephalopathy syndrome in children with cancer.

Authors:  E Brannon Morris; Fred H Laningham; John T Sandlund; Raja B Khan
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

5.  Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.

Authors:  C D Bloomfield; C Shuma; L Regal; P P Philip; D K Hossfeld; A M Hagemeijer; O M Garson; B A Peterson; M Sakurai; G Alimena; R Berger; J D Rowley; T Ruutu; F Mitelman; G W Dewald; J Swansbury
Journal:  Cancer       Date:  1997-12-01       Impact factor: 6.860

6.  Childhood leukemia: central nervous system abnormalities during and after treatment.

Authors:  C Y Chen; R A Zimmerman; S Faro; L T Bilaniuk; T Y Chou; P T Molloy
Journal:  AJNR Am J Neuroradiol       Date:  1996-02       Impact factor: 3.825

Review 7.  Treatment of childhood acute nonlymphoblastic leukemia: a review.

Authors:  F Boulad; N A Kernan
Journal:  Cancer Invest       Date:  1993       Impact factor: 2.176

8.  Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.

Authors:  E L Sievers; B J Lange; J D Buckley; F O Smith; D A Wells; C A Daigneault-Creech; K E Shults; I D Bernstein; M R Loken
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

9.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.

Authors:  Y Ravindranath; A M Yeager; M N Chang; C P Steuber; J Krischer; J Graham-Pole; A Carroll; S Inoue; B Camitta; H J Weinstein
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245

10.  Late cranial MRI after cranial irradiation in survivors of childhood cancer.

Authors:  E Pääkkö; K Talvensaari; J Pyhtinen; M Lanning
Journal:  Neuroradiology       Date:  1994-11       Impact factor: 2.804

View more
  15 in total

1.  An adolescent with suspected intracranial hypertension - ALL is not what it seems.

Authors:  Asgeir Store Jakola; Sasha Gulati
Journal:  Childs Nerv Syst       Date:  2012-01-28       Impact factor: 1.475

Review 2.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

3.  Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Authors:  Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

4.  Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.

Authors:  Kerui Wu; Koji Fukuda; Fei Xing; Yingyu Zhang; Sambad Sharma; Yin Liu; Michael D Chan; Xiaobo Zhou; Shadi A Qasem; Radhika Pochampally; Yin-Yuan Mo; Kounosuke Watabe
Journal:  J Biol Chem       Date:  2015-02-17       Impact factor: 5.157

5.  Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.

Authors:  Claudiu T Supuran
Journal:  World J Clin Oncol       Date:  2012-07-10

6.  Leukemia-derived exosomes and cytokines pave the way for entry into the brain.

Authors:  Ichiko Kinjyo; Denis Bragin; Rachel Grattan; Stuart S Winter; Bridget S Wilson
Journal:  J Leukoc Biol       Date:  2019-01-31       Impact factor: 4.962

7.  Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.

Authors:  Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Veronika Northrup; Lu Chen; Megan Nicoletti; Bruce Bostrom; Linda Stork; Joseph P Neglia
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  Headache types, related morbidity, and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross sectional study.

Authors:  Zsila S Sadighi; Kirsten K Ness; Melissa M Hudson; E Brannon Morris; Davonna S Ledet; Ching-Hon Pui; Scott C Howard; Kevin R Krull; Emily Browne; Debbie Crom; Pamela S Hinds; Liang Zhu; Deokumar Srivastava; Raja B Khan
Journal:  Eur J Paediatr Neurol       Date:  2014-07-05       Impact factor: 3.140

9.  Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy.

Authors:  Nirav Patel; Benjamin J RIch; Shareen Patel; Justin M Watts; Ronald Benveniste; Matthew Abramowitz; Arnold Markoe; Daniel G Eichberg; Ricardo J Komotar; Marcarena De La Fuente; Joshua Pasol; Tejan Diwanji
Journal:  Cureus       Date:  2021-05-24

10.  Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.

Authors:  Guillermo Gervasini; Jose M Vagace
Journal:  Front Genet       Date:  2012-11-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.